Enlivex (ENLV) Total Current Liabilities (2013 - 2025)
Enlivex (ENLV) posted quarterly Total Current Liabilities of $9.0 million for Q4 2025, up 137.46% year-over-year from $3.8 million in Q4 2024, and up 197.62% quarter-over-quarter from $3.0 million in Q3 2025.
Enlivex (ENLV) Total Current Liabilities (2013 - 2025) Analysis & Trends
Enlivex's Total Current Liabilities history runs 13 years deep, the most recent figure standing at $9.0 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 137.46% year-over-year to $9.0 million; the TTM figure through Dec 2025 stood at $9.0 million (up 137.46% YoY), while the FY2025 annual figure was $9.0 million, up 137.46% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $9.0 million, up from $3.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $9.0 million in Q4 2025, with the low at $2.8 million in Q3 2024.
- The 5-year median for Total Current Liabilities is $4.6 million (2021), against an average of $4.6 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities sank 43.08% in 2024, then surged 137.46% in 2025.
- Enlivex's Total Current Liabilities stood at $4.7 million in 2021, then soared by 40.04% to $6.6 million in 2022, then fell by 8.26% to $6.1 million in 2023, then slumped by 37.32% to $3.8 million in 2024, then soared by 137.46% to $9.0 million in 2025.
- Business Quant data shows ENLV's Total Current Liabilities at $9.0 million in Q4 2025, $3.0 million in Q3 2025, and $3.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 9.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.02 Mn |
| Sep 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 3.33 Mn |
| Mar 31, 2025 | 3.14 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.84 Mn |
| Mar 31, 2024 | 3.61 Mn |
| Dec 31, 2023 | 6.06 Mn |
| Sep 30, 2023 | 4.34 Mn |
| Jun 30, 2023 | 4.99 Mn |
| Mar 31, 2023 | 5.45 Mn |
| Dec 31, 2022 | 6.61 Mn |
| Sep 30, 2022 | 4.53 Mn |
| Jun 30, 2022 | 4.21 Mn |
| Mar 31, 2022 | 5.74 Mn |
| Dec 31, 2021 | 4.72 Mn |
| Sep 30, 2021 | 4.73 Mn |
| Jun 30, 2021 | 4.58 Mn |
| Mar 31, 2021 | 4.91 Mn |